Abiomed Statistics
Share Statistics
Abiomed has 45.09M
shares outstanding. The number of shares has increased by -0.45%
in one year.
| Shares Outstanding | 45.09M |
| Shares Change (YoY) | -0.45% |
| Shares Change (QoQ) | -1.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 110.28 and the forward
PE ratio is null.
Abiomed's PEG ratio is
-2.76.
| PE Ratio | 110.28 |
| Forward PE | n/a |
| PS Ratio | 14.59 |
| Forward PS | n/a |
| PB Ratio | 10.01 |
| P/FCF Ratio | 60.3 |
| PEG Ratio | -2.76 |
Financial Ratio HistoryEnterprise Valuation
Abiomed has an Enterprise Value (EV) of 14.92B.
| EV / Sales | 14.46 |
| EV / EBITDA | 37.23 |
| EV / EBIT | 52.28 |
| EV / FCF | 59.77 |
Financial Position
The company has a current ratio of 7.05,
with a Debt / Equity ratio of 0.
| Current Ratio | 7.05 |
| Quick Ratio | 6.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 7.48 |
Financial Efficiency
Return on Equity is 9.08% and Return on Invested Capital is 17.76%.
| Return on Equity | 9.08% |
| Return on Assets | 8.16% |
| Return on Invested Capital | 17.76% |
| Revenue Per Employee | $515,103.84 |
| Profits Per Employee | $68,150.27 |
| Employee Count | 2,003 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2 |
Taxes
| Income Tax | 54.05M |
| Effective Tax Rate | 28.37% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0, so Abiomed's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 348.85 |
| 200-Day Moving Average | 292 |
| Relative Strength Index (RSI) | 76.23 |
| Average Volume (20 Days) | 1,703,123 |
Income Statement
In the last 12 months, Abiomed had revenue of 1.03B
and earned 136.5M
in profits. Earnings per share was 3.
| Revenue | 1.03B |
| Gross Profit | 843.6M |
| Operating Income | 372.69M |
| Net Income | 136.5M |
| EBITDA | 400.78M |
| EBIT | 472.37M |
| Earnings Per Share (EPS) | 3 |
Full Income StatementBalance Sheet
The company has 132.82M in cash and 0 in
debt, giving a net cash position of 132.82M.
| Cash & Cash Equivalents | 132.82M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | 964.51M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 285.39M
and capital expenditures -35.76M, giving a free cash flow of 249.63M.
| Operating Cash Flow | 285.39M |
| Capital Expenditures | -35.76M |
| Free Cash Flow | 249.63M |
| FCF Per Share | 5.49 |
Full Cash Flow StatementMargins
Gross margin is 81.76%, with operating and profit margins of 36.12% and 13.23%.
| Gross Margin | 81.76% |
| Operating Margin | 36.12% |
| Pretax Margin | 18.47% |
| Profit Margin | 13.23% |
| EBITDA Margin | 38.84% |
| EBIT Margin | 36.12% |
| FCF Margin | 24.19% |
